The lytic cycle of Epstein-Barr virus is associated with decreased expression of cell surface major histocompatibility complex class I and class II molecules

Journal of Virology

Volumn 76, Issue 16, 2002, Pages 8179-8188

  Keating, Sinéad ^a   Prince, Stuart ^a   Jones, Matthew ^a   Rowe, Martin ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; B7 ANTIGEN; CD19 ANTIGEN; CD40 ANTIGEN; CD86 ANTIGEN; INTERCELLULAR ADHESION MOLECULE 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2;

ANTIGEN EXPRESSION; ANTIGEN RECOGNITION; ARTICLE; CELL SURFACE; CONTROLLED STUDY; CYTOLYSIS; CYTOTOXIC T LYMPHOCYTE; EPSTEIN BARR VIRUS; HUMAN; HUMAN CELL; IMMUNE SYSTEM; LATENT VIRUS INFECTION; MIXED LYMPHOCYTE REACTION; PRIORITY JOURNAL; TRANSACTIVATION; VIRUS CELL INTERACTION; VIRUS REPLICATION;

ANTIGEN PRESENTATION; CELL LINE, TRANSFORMED; DNA-BINDING PROTEINS; DOWN-REGULATION; HERPESVIRUS 4, HUMAN; HISTOCOMPATIBILITY ANTIGENS CLASS I; HISTOCOMPATIBILITY ANTIGENS CLASS II; HUMANS; NF-KAPPA B; T-LYMPHOCYTES, CYTOTOXIC; TRANS-ACTIVATORS; VIRAL MATRIX PROTEINS; VIRAL PROTEINS;

EID: 0036318698     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.76.16.8179-8188.2002     Document Type: Article

References (64)

1. Epstein-Barr virus nuclear antigen 2 (EBNA2) induces expression of the virus-coded latent membrane protein (LMP)
2. Epstein-Barr virus immediate-early proteins BZLF1 and BRLF1 activate the ATF2 transcription factor by increasing the levels of phoxphorylated p38 and c-Jun N-terminal kinases
3. The Epstein-Barr virus BZLF1 protein interacts physically and functionally with the histone acetylase CREB-binding protein
4. Epstein-Barr virus immediate-early protein BZLF1 is SUMO-1 modified and disrupts promyelocytic leukemia bodies
5. Viral mechanisms of immune evasion
6. Phosphatidylcholine hydrolysis activates NF-κB and increases human immunodeficiency virus replication in human monocytes and T lymphocytes
7. Establishment in continuous culture of a new type of lymphocyte from a "Burkitt like" malignant lymphoma (line D.G.-75)
8. + T cell responses to EBV EBNAI: HLA class I presentation of the (Gly-Ala)-containing protein requires exogenous processing
9. Specific cytotoxic T lymphocytes recognize the immediate-early transactivator Zta of Epstein-Barr virus
10. 1 cell cycle arrest through induction of cyclin-dependent kinase inhibitors
11. Antigen processing and presentation by EBV-carrying cell lines: Cell-phenotype dependence and influence of the EBV encoded LMP1
12. Induction of the lytic viral cycle in Epstein Barr virus carrying Burkitt lymphoma lines is accompanied by increased expression of major histocompatibility complex molecules
13. Inactivation of NF-κB by EBV BZLF-1-encoded ZEBRA protein in human T cells
14. + T cells in vitro
15. Replication of Epstein-Barr virus oriLyt: Lack of a dedicated virally encoded origin-hinding protein and dependence on Zta in cotransfection assays
16. Trans-acting requirements for replication of Epstein-Barr virus oriLyt
17. Autoregulation of Epstein-Barr virus putative lytic switch gene BZLF1
18. Cytostatic effect of Epstein-Barr virus latent membrane protein-1 (LMP1) analysed using tetracycline-regulated expression
19. Epstein-Barr virus latent membrane protein-1 (LMP1) C-terminus activation region 2 (CTAR2) maps to the far C-terminus and requires oligomerisation for NF-κB activation
20. Downregulation of cell adhesion molecules LFA-3 and 1CAM-1 in Epstein-Barr virus-positive Burkitt's lymphoma underlies tumor cell escape from virus-specific T cell surveillance
21. The bZIP transactivator BZIP of Epstein-Barr virus, BZLF1, functionally and physically interacts with the p65 subunit of NF-κB
22. Major histocompatibility complex class I molecules are down-regulated at the cell surface by the K5 protein encoded by Kaposi's sarcoma-associated herpesvirus/human herpesvirus-8
23. Interference with antigen processing by viruses
24. The Epstein-Barr virus latent membrane protein-1 (LMP1) mediates activation of NF-κB and cell surface phenotype via two effector regions in its carboxyterminal cytoplasmic domain
25. Down-regulation of major histocompatibility complex class I molecules by Kaposi's sarcoma-associated herpesvirus K3 and K5 proteins
26. Cells expressing the Epstein-Bart virus growth program are present in and restricted to the naive B-cell subset of healthy tonsils
27. Epstein-Barr virus and its replication
28. Production of monoclonal antibody to a late intracellular Epstein-Barr virus-induced antigen
29. Inhibition of antigen processing by the internal repeat region of the Epstein-Barr virus nuclear antigen-1
30. Prolonged inhibitory effect of 9-(1,3-dihydroxy-2-propoxymethyl)guanine against replication of Epstein-Barr virus
31. Down-regulation of class-I HLA antigens and of the Epstein-Barr virus (EBV)-encoded latent membrane protein (LMP) in Burkitt's lymphoma lines
32. Characterization of intercellular adhesion molecule-I regulation by Epstein-Barr virus-encoded latent membrane protein-1 identifies pathways thai cooperate with nuclear factor κB to activate transcription
33. Viral effects on antigen processing
34. Identification of the site of Epstein-Barr virus persistence in vivo as a resting B cell
35. Inhibition of IFN-γ signaling by an Epstein-Barr virus immediate-early protein
36. RelB nuclear translocation mediated by C terminal activator regions of Epstein-Barr virus-encoded latent membrane protein 1 and its effect on antigen-presenting function in B cells
37. KSHV-K5 inhibits phosphorylation of the major histocompatibility complex class I cytoplasmic tail
38. Immediate-early transactivator Rta of Epstein-Barr virus (EBV) shows multiple epitopes recognized by EBV-specific cytotoxic T lymphocytes
39. A new tumour-derived transforming strain of Epstein-Barr virus
40. Viral strategies of immune evasion
41. Epstein-Barr virus latent gene expression in uncultured peripheral blood lymphocytes
42. Identification of a rare Epstein-Barr virus variant that enhances early antigen expression in Raji cells
43. Epstein-Barr virus
44. Human cytotoxic T lymphocyte responses to Epstein-Barr virus infection
45. Role of c-myc regulation in Zta-mediated induction of the cyclin-dependent kinase inhibitors p21 and p27 and cell growth arrest
46. The spliced BZLF1 gene of Epstein-Barr virus (EBV) transactivates an early EBV promoter and induces the virus productive cycle
47. Epstein-Barr virus-positive Burkitt's lymphoma cells not recognized by virus-specific T-cell surveillance
48. Idendfication and expression of a nuclear antigen from the genomic region of the Jijoye strain of Epsein-Barr virus that is missing in its non-immortalizing deletion mutant, P3HR-1
49. Monoclonal antibodies to the latent membrane protein of Epstein-Barr virus reveal heterogeneity of the protein and inducible expression in virus-transformed cells
50. Detection of EBV latent proteins by Western bloiting
51. Restoration of endogenous antigen processing in Burkitt's lymphoma cells by Epstein-Barr virus latent membrane protein-1: Coordinate up-regulation of peptide transporters and HLA-class 1 antigen expression
52. Three pathways of Epstein-Barr virus gene activation from EBNA1 positive latency in B lymphocytes
53. Differences in B cell growth phenotype reflect novel patterns of Epstein-Barr virus latent gene expression in Burkitt's lymphoma cells
54. A transcription factor with homology to the AP-1 family links RNA transcription and DNA replication in the lytic cycle of Epstein-Barr virus
55. Immediate early and early lytic cycle proteins are frequent targets of the Epstein-Barr virus-induced cytotoxic T cell response
56. Inhibition of MHC class 1-restricted antigen presentation by gamma-2 herpesviruses
57. Synchronous and sequential activation of latently infected Epstein-Barr virus genomes
58. Epstein-Barr virus latency in blood mononuclear cells: Analysis of viral gene transcription during primary infection and in the carrier state
59. Epstein-Barr virus latent membrane protein (LMP1) and nuclear proteins 2 and 3C are effectors of phenotypic changes in B lymphocytes: EBNA-2 and LMP1 cooperatively induce CD23
60. Differentiation-associated expression of the Epstein-Barr virus BZLP1 transactivator protein in oral hairy leukoplakia
61. The amino-terminal C/H1 domain of CREB binding protein mediates Zta transcriptional activation of latent Epstein-Barr virus
62. Epstein-Barr virus (EBV) latent membrane-protein-1 increases HLA class-II expression in an EBV-negative B-cell line
63. Functional and physical interaction between p53 and BZLF1: Implications for Epstein-Barr virus latency
64. Proto-oncogene PML controls genes devoted to MHC class 1 antigen presentation